ARPA-H Announces Three Research Teams Developing Osteoarthritis Treatments in Animal Studies

The Advanced Research Projects Agency for Health (ARPA-H), a U.S. federal agency, launched a major initiative three years ago to develop treatments for osteoarthritis. Osteoarthritis involves the degeneration of joint cartilage and bone, affecting an estimated 32 million people in the United States.

The agency committed tens of millions of dollars over five years to support research aimed at finding effective solutions for the condition. ARPA-H announced on Monday that three funded research teams have achieved preliminary results in animal models.

The program focuses initially on knee osteoarthritis, though the researchers indicate the approaches may apply to other joints. Under the contracts, the teams must initiate human clinical trials within 18 months.

the teams have developed injectable or infusible treatments that promote the regrowth of bone and cartilage. One team is based at Duke University, and the other at the University of Colorado, Boulder. These methods have been tested only in animals to date.

A third team, at Columbia University, has explored a technique that could enable the regrowth of an entire knee joint in animal studies. All findings remain at the preclinical stage, with no human testing reported yet.

not involved in the research have reviewed the preliminary data. The results come from animal studies, which provide foundational evidence but require validation in human subjects to assess safety and efficacy. Osteoarthritis contributes to significant mobility limitations and healthcare costs for affected individuals, particularly older adults and those with joint injuries.

Successful translation to human treatments could address a major public health challenge. ARPA-H's program underscores federal efforts to accelerate medical innovations through targeted funding.